MENU
In this issue

Cover Focus

The Central Vein Sign image
TOP

The Central Vein Sign

Is 1.5 T MRI still relevant for diagnosis of multiple sclerosis?

Evanthia Bernitsas, MD

Point/Counterpoint: Neurofilament Light image

Point/Counterpoint: Neurofilament Light

Ready for prime time as a biomarker for multiple sclerosis or not?

Adil Javed, MD, PhD; and James Stankiewicz MD, FAAN

Sphingosine-1-Phosphate Modulators for Multiple Sclerosis image

Sphingosine-1-Phosphate Modulators for Multiple Sclerosis

Sphingosine-1-phosphate modulators may act through more than just inhibition of neuroimmune and neuroinflammatory effects of multiple sclerosis.

Mark B. Skeen, MD

AntiCD20+ Agents image

AntiCD20+ Agents

AntiCD20+ agents are among the highest efficacy treatments for multiple sclerosis.

Brian Barry, MD; and Robert K. Shin, MD

Cladribine image

Cladribine

Cladribine is an effective oral treatment for multiple sclerosis with potential for long-term remission.

Crystal Dixon, MD; Miguel Melo-Bicchi, MD; and Kottil W. Rammohan, MD

Drugs in Development for Multiple Sclerosis image

Drugs in Development for Multiple Sclerosis

Stem cells, tyrosine kinase inhibitors, remyelinating agents, metabolically active molecules, and more are being tested as potential new disease-modifying treatments.

Konstantin Balashov, MD, PhD

February 2020 teaser
TOP

Point/Counterpoint: Food and Drug Administration Multiple Sclerosis Categorization Changes

Are the changes a step forward or a step back?

Svetlana Primma Eckert, MD; Bianca Weinstock-Guttman, MD; and Stephen Krieger, MD

Multiple Sclerosis Treatment in Racial and Ethnic Minorities image

Multiple Sclerosis Treatment in Racial and Ethnic Minorities

Systematic literature review shows little evidence to guide treatment.

Michael V. Robers, MD; Deepak Soneji, MD, PhD; and Lilyana Amezcua, MD, MS

Read Issue